Seifert PS, Roth I, Schmid W, et al. 1992. CD59, (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack in human atherosclerotic lesions. Atherosclerosis, 96:135–45. Shandelya SM, Kuppusamy P, Herskowitz A, et al. 1993. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation, 88:2812–26. Shernan SK, Fitch JC, Nussmeier NA, et al. 2004. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg, 77:942–9. Siegel J, Rent R, Gewurz H. 1974. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med, 140:631–47. Smith PK, Carrier M, Chen JC, et al. 2006. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time. Ann Thorac Surg, 82:781–8. Socie G, Mary JY, de Gramont A, et al. 1996. Paroxysmal nocturnal hemo- globinuria: Long-term follow-up and prognostic factors. French society for haematology. Lancet, 348:573–7. Speidl WS, Exner M, Amighi J, et al. 2005. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J, 26:2294–9. Spitzer D, Unsinger J, Bessler M, et al. 2004. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol, 40:911–9. Takeda J, Miyata T, Kawagoe K, et al. 1993. Deﬁciency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell, 73:703–11. Théroux P, Armstrong PW, Mahaffey KW, et al. 2005. Prognostic signiﬁcance of blood markers of inﬂammation in patients ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J, 26:1964–70. Thielmann M, Marggraf G, Neuhauser M, et al. 2006. Administration of C1- esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg, 30:285–93. Thomas TC, Rollins SA, Rother RP, et al. 1996. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol, 33:1389–401. Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al. 2006. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant, 21:3115–21. Turnberg D, Botto M, Warren J, et al. 2003. CD59a deﬁciency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol, 14:2271–9. Väkevä A, Laurila P, Meri S. 1992. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Laboratory Invest, 67:608–16. Anticomplement therapy Vakeva AP, Agah A, Rollins SA, et al. 1998. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation, 97:2259–67. Verma S, Fedak PW, Weisel RD, et al. 2002. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation, 105:2332–6. Verrier ED, Shernan SK, Taylor KM, et al. 2004. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA, 291:2319–27. Vlaicu R, Rus HG, Niculescu F, et al. 1985. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis, 55:35–50. Volanakis JE. 1982. Complement activation by C-reactive protein complexes. Ann NY Acad Sci, 389:235–50. Volanakis JE, Kaplan MH. 1974. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea-pig complement by CRP complexes: requirement for human Clq. J Immunol, 113:9–17. Wang Y, Hu Q, Madri JA, et al. 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody speciﬁc for complement component C5. Proc Natl Acad Sci U S A, 93(16):8563–8. Ward PA. 2008. Role of the complement in experimental sepsis. J Leukoc Biol, 83:467–70. Weiler JM. 1983. Polyions regulate the alternative ampliﬁcation pathway of complement. Immunopharmacol, 6:245–55. Weiler JM, Yurt RW, Fearon DT, et al. 1978. Modulation of the formation of the ampliﬁcation convertase of C3b, Bb, by native and commercial heparin. J Exp Med, 147:409–21. Weisman HF, Bartow T, Leppo MK, et al. 1990a. Recombinant soluble CR1 suppressed complement activation, inﬂammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians, 103:64–72. Weisman HF, Bartow T, Leppo MK, et al. 1990b. Soluble human comple- ment receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science, 249:146–51. Welch TR, Frenzke M, Witte D, et al. 2002. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol, 130:43–8. Wurzner R, Schulze M, Happe L, et al. 1991. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inﬂamm, 8:328–40. Yasuda M, Takeuchi K, Hiruma M, et al. 1990. The complement system in ischemic heart disease. Circulation, 81:156–63. Zhang HF, Yu J, Bajwa E, et al. 1999. Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest, 103:55–61. Zhang H, Lu S, Morrison SL, et al. 2001. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem, 276:27290–5. Biologics:Targets & Therapy 2008:2(4) 685